RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Sponsor
University of Florence
Study ID
NCT06409832
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rimegepant 75 mg — DRUG
    Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention

Study Details

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

Key Dates

Start date
Mar 26, 2024
Status verified
Jun 2026
Primary completion
Jan 1, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Episodic migraine
    Patients affected by an episodic pattern migraine(\< 15 monthly headache days) with or without aura according to ICHD-III criteria.

Primary Outcome Measure

Changes in migraine frequency after three months of treatment [ Time Frame: Baseline (T0) - 3 months of treatment with rimegepant (T3) ]

Central Contacts

Related Studies